FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions refers to pharmaceutics and concerns providing a liquid stables antibody-containing composition, and a method for inhibiting antibody molecules dimerisation in the liquid composition. The composition contains arginine 40-1000 mM, methionine 10-200 mM and antibody in the concentration of 50-300 mg/ml.
EFFECT: group of inventions provides preparing the stable composition for subcutaneous administration for the purpose of preventing long-term storage antibody dimerisation and deamidation.
21 cl, 3 ex, 4 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| LIQUID COMPOSITION CONTAINING HIGH CONCENTRATION ANTIBODY | 2019 |
|
RU2795116C2 |
| LIQUID COMPOSITION CONTAINING HIGH CONCENTRATION ANTIBODY | 2013 |
|
RU2701181C2 |
| PHARMACEUTICAL FORMULATION CONTAINING ADVANCED ANTIBODY MOLECULES | 2010 |
|
RU2565809C2 |
| HUMANIZED ANTI-EPIREGULIN-ANTIBODY AND ANTI-TUMOUR THERAPEUTIC AGENT CONTAINING THIS ANTIBODY AS ACTIVE INGREDIENT | 2012 |
|
RU2634383C2 |
| SOLUTION PREPARATION CONTAINING STABILIZED ANTIBODIES | 2011 |
|
RU2653447C2 |
| METHOD OF MODIFICATION OF POLYPEPTIDE FOR PURIFICATION OF POLYPEPTIDE MULTIMERS | 2010 |
|
RU2606264C2 |
| STABLE LIQUID PHARMACEUTICAL COMPOSITION | 2018 |
|
RU2773747C2 |
| COMPOSITIONS OF ANTIBODIES | 2005 |
|
RU2426554C2 |
| COMPOSITION CONTAINING ANTIBODY | 2010 |
|
RU2609658C2 |
| METHOD OF TREATING INTERLEUKIN-6-DEPENDENT DISEASES | 2004 |
|
RU2509574C2 |
